The Importance of Maintaining Positive Partnerships with Contract Manufacturing Organisations (CMOs) and Contract Development and Manufacturing Organisations (CDMOs)

Due to the pandemic, the medical needs of populations worldwide are increasing and there is a huge demand for pharmaceutical products, causing CMOs and CDMOs to be increasingly sought after by pharmaceutical companies for their specialist equipment, facilities, labour force and cost-effective production. However, as large pharmaceutical companies start to develop in-house manufacturing capabilities, there is more and more competition between CMOs and CDMOs to prove they are the best partner.

Ahead of this year's Pharma Contract Manufacturing 2022 event, we spoke to Ulrich Rümenapp, Head of Launch Preparation and Coordination at Bayer AG, about the importance of maintaining positive partnerships with CMOs and CDMOs, to help you create and maintain positive partnerships with your CMOs and CDMOs, and build industry resilience.

Download the full interview now >>

Additional benefits to downloading the full interview:

• Discover how the last 18 months has impacted CMO and/or CDMO partnerships
• Learn about the greatest challenges of complex product manufacturing, and the top tips for overcoming these challenges
• Find out more about the benefits and opportunities of CMO and/or CDMO partnerships
• A summary of the key initiatives for maintaining positive CMO and/or CDMO partnerships over the next 2 years